Oncotarget

Research Papers:

Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome

Aida Kiviniemi _, Maria Gardberg, Katri Kivinen, Jussi P. Posti, Ville Vuorinen, Jussi Sipilä, Melissa Rahi, Matti Sankinen and Heikki Minn

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:49123-49132. https://doi.org/10.18632/oncotarget.17097

Metrics: PDF 829 views  |   HTML 2503 views  |   ?  


Abstract

Aida Kiviniemi1,2, Maria Gardberg3, Katri Kivinen4, Jussi P. Posti5, Ville Vuorinen5, Jussi Sipilä6,7, Melissa Rahi5, Matti Sankinen5 and Heikki Minn8

1Department of Radiology, Medical Imaging Center of Southwest Finland, Turku University Hospital and University of Turku, Turku, Finland

2Turku PET Center, Turku University Hospital and University of Turku, Turku, Finland

3Department of Pathology, Turku University Hospital and University of Turku, Turku, Finland

4TYKSLAB, Laboratory of Molecular Genetics, Turku University Hospital, Turku, Finland

5Division of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital and University of Turku, Turku, Finland

6Department of Neurology, North Karelia Central Hospital, Joensuu, Finland

7Division of Clinical Neurosciences, Department of Neurology, Turku University Hospital and University of Turku, Turku, Finland

8Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland

Correspondence to:

Aida Kiviniemi, email: aida.kiviniemi@utu.fi

Keywords: glioma, somatostatin receptor, oligodendroglioma, IDH mutation, prognosis

Received: February 20, 2017     Accepted: April 03, 2017     Published: April 13, 2017

ABSTRACT

Somatostatin receptor subtype 2A (SSTR2A) is a potential therapeutic target in gliomas. Data on SSTR2A expression in different glioma entities, however, is particularly conflicting. Our objective was to characterize SSTR2A status and explore its impact on survival in gliomas classified according to the specific molecular signatures of the updated WHO classification. In total, 184 glioma samples were retrospectively analyzed for SSTR2A expression using immunohistochemistry with monoclonal antibody UMB-1. Double staining with CD68 was used to exclude microglia and macrophages from analyses. SSTR2A staining intensity and its localization in tumor cells was evaluated and correlated with glioma entities and survival. Diagnoses included 101 glioblastomas (93 isocitrate dehydrogenase (IDH) -wildtype, 3 IDH-mutant, 5 not otherwise specified (NOS)), 60 astrocytomas (22 IDH-wildtype, 37 IDH-mutant, 1 NOS), and 23 oligodendrogliomas (19 IDH-mutant and 1p/19q-codeleted, 4 NOS). SSTR2A expression significantly associated with oligodendrogliomas (79% SSTR2A positive) compared to IDH-mutant or IDH-wildtype astrocytomas (27% and 23% SSTR2A positive, respectively), and especially glioblastomas of which only 13% were SSTR2A positive (p < 0.001, Fisher’s exact test). The staining pattern in glioblastomas was patchy whereas more homogeneous membranous and cytoplasmic staining was detected in oligodendrogliomas. Positive SSTR2A was related to longer overall survival in grade II and III gliomas (HR 2.7, CI 1.2–5.8, p = 0.013). In conclusion, SSTR2A expression is infrequent in astrocytomas and negative in the majority of glioblastomas where it is of no prognostic significance. In contrast, oligodendrogliomas show intense membranous and cytoplasmic SSTR2A expression, which carries potential diagnostic, prognostic, and therapeutic value.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17097